All News
Tofighi et al. VTE in SLE nephritis. 10% VTE, 5.2% VTE after SLE nephritis diagnosis. Risks - Black patients, ds-DNA+, SDI, aPL+, SLEDAI. @RheumNow #ACR22 Abstr#0541 https://t.co/G6q0qvirf7 https://t.co/B8STBTMy14
Richard Conway RichardPAConway ( View Tweet)
Prelude to a Meeting #ACR22
https://t.co/ESjDnNue1H https://t.co/EHt5tgFOn3
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR Best Abstracts - Day 1
The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).
https://t.co/ndSBqYszlo https://t.co/vOHtLTFux6
Links:
Dr. John Cush RheumNow ( View Tweet)
Across 9 trials of Upadacitinib in RA, PsA and AS, 40%–50% of patients had ≥ 2 CV risk factors, ≥ 65 years 6%–23%. Rates of adjudicated MACE and VTE with UPA were infrequent, consistent with background rates in RA, PsA, and AS Abst 0510 https://t.co/HDkQ6ELnAy #ACR22 @RheumNow https://t.co/SRJYdFFNIQ
Dr. Antoni Chan synovialjoints ( View Tweet)
New concept of sJIA to MAS as a continuum on the spectrum of disease severity. Molecular basis via impact of mTORC1 (mechanistic target of rapamycin complex 1) inhibition in Il1rn-/- mice. Looking forward to the full paper. Huang Z Abs004 https://t.co/3OtIp90PnG #ACR22 @RheumNow https://t.co/PPHQj8bYKu
Dr. Antoni Chan synovialjoints ( View Tweet)
How can we differentiate statin-assoc autoimmune necrotizing myopathy from toxic statin #myopathy?🔎
Remember this important slide👇
#ACR22 @Rheumnow #acrreview https://t.co/hKMJuGDJWt
sheila RHEUMarampa ( View Tweet)
Statin therapy may exacerbate underlying neuromuscular disorders.
‼️REMEMBER☝️The only ABSOLUTE contraindication to statins are pts who are HMGCR+
#ACR22 @RheumNow #acrreview https://t.co/A3XGHlrm0X
sheila RHEUMarampa ( View Tweet)
Interesting study by Dr Ai Li Yeo and colleagues on repetitive anti-dsDNA testing and flare prediction:
🔅Fluctuations (⬆️and ⬇️) in anti-dsDNA >2 fold was assoc'd w/⬆️flares in all groups including persistently + pts.
#ACR22 @RheumNow ABST#327 https://t.co/q0WXnIwV4A
sheila RHEUMarampa ( View Tweet)
In this study, Dr. Niti Goel shows the under-reporting of race & ethnicity in publications of #psoriaticarthritis clinical trials
🧐Participant diversity is important to consider since different races & ethnicities may respond differently to therapies
#ACR22 @RheumNow ABST0090 https://t.co/BzHpuHYVI5
sheila RHEUMarampa ( View Tweet)
Post hoc analysis from the SELECT-PsA 1 trial by Dr. @DrLauraCoates and team:
💊Pts on UPA showed greater improvement from BL in RAPID3 vs. ADA in all visits
💊Pts on UPA had better responses in all assessments vs. PBO
Reassuring data. #ACR22 @RheumNow ABST0192 https://t.co/NgeUU5bPPf
sheila RHEUMarampa ( View Tweet)
Abstr 0383 evaluated the use of previously developed AI algorithm to detect sacroiliitis in a new axSpA cohort. The neural network achieved
-Sensitivity 82%; specificity 81%
-PPV 0.89; NPV 0.70
https://t.co/PDSsiMIQUc
@RheumNow #ACR22 #AI #MachineLearning #AxSpA https://t.co/mXUHUowGhQ
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abstr #0195 examined acceptance of Virtual Reality among pts w/ rheumatic diseases (RD)
- VR naïve & experienced were willing to use VR to manage their RD
- VR experienced pts had ↑ % of perceived usefulness & anticipated enjoyment of VR in dx and mgmt of RD
@RheumNow #ACR22 https://t.co/r7X8Kqp8UN
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abst0338 #ACR22 Transition from CLE to SLE
324 cases of incident cutaneous lupus, mean f/u 8 years
26 pts developed SLE. 5.2% transition by 5 years, <3% risk every 5 yrs from 5-20 years
Risk factors: SCLE, younger age, recent diagnosis
@RheumNow #ACRBest https://t.co/JFcUIkfA9n
Eric Dein ericdeinmd ( View Tweet)
Year in Review #ACR22
Pre-expos PPx for COVID!
Tix-Cil (Evusheld): risk reduction 77%
Cardiac AES 0.6% vs placebo 0.2%
Only 3.3% were on immunosuppression
But Israeli study with immunosuppressed:
92% half as likely to be hospitalized or die
1/2 less infections
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Ab1291 #ACR22: 🔥Ignite🔥
@DavidLeverenz: Constructed a model to identify telehealth visits - PPV 0.8, sensitivity 0.39 - better than existing practice (PPV 0.77)
Predictors: age, diagnoses, medications, RAPID3, provider preference for 💻🩺
3 mo pilot program predictive
@RheumNow https://t.co/Iey87SVGv4
Eric Dein ericdeinmd ( View Tweet)
Very important point about statin induced myopathy by Dr. Christopher-Stine.
If 1) history of statin exposure, 2) typical symptoms of myositis 3) HMGCR ab positive — do NOT need biopsy and can treat as statin associated necrotizing autoimmune myopathy!
@RheumNow #ACR22 https://t.co/VHxPRkCWwj
Robert B Chao, MD doctorRBC ( View Tweet)
Among ANCA-vasculitis hospitalizations, A Fib found to be most common CV condition. Females had fewer CV complications, lower in-hospital mortality & shorter length of stay compared to males. Abs 0434 #ACR22 https://t.co/2IikApUdvE https://t.co/16ggVScs3a
Dr. Rachel Tate uptoTate ( View Tweet)
SELECT-AXIS 2 subgroup analysis. UPA demonstrated improved efficacy vs PBO at Wk 14 across all evaluated subgroups of pts with bDMARD-IR AS. No new safety signals. @XBaraliakos et al, Abs 0414 #ACR22 https://t.co/lTfm68XlEY https://t.co/PaWdrOljMO
Dr. Rachel Tate uptoTate ( View Tweet)
Do you check ANCAs in your ILD pts? Abs 0438 at #ACR22 suggests you should! @RheumNow
https://t.co/W8rRAdWFQh https://t.co/RQfcQQUVzI
Dr. Rachel Tate uptoTate ( View Tweet)
Headed to the #ACR22 Fellows in Training (FIT) session for a round table on keeping up with the medical literature!
As usual, updated handout for this year 🤓
@MithuRheum Wish I had thought to ask you for help w/my graphics-game! Not my strength hahaha
#ACRAmbassador https://t.co/Tg4ZT262rU
Mike Putman EBRheum ( View Tweet)